Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21789634 | 1.00 | STING1 (0.71) | STING1 | |
| SCHEMBL23855765 | 0.98 | STING1 (0.70) | STING1 | |
| SCHEMBL23855730 | 0.98 | STING1 (0.70) | STING1 | |
| SCHEMBL23637116 | 0.97 | STING1 (0.69) | STING1 | |
| SCHEMBL23855715 | 0.95 | STING1 (0.65) | STING1 | |
| SCHEMBL21790355 | 0.95 | STING1 (0.65) | STING1 | |
| SCHEMBL23637170 | 0.94 | STING1 (0.64) | STING1 | |
| SCHEMBL21789992 | 0.94 | STING1 (0.63) | STING1 | |
| SCHEMBL23855728 | 0.94 | STING1 (0.67) | STING1 | |
| SCHEMBL21789647 | 0.94 | STING1 (0.64) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3848366-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848366-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| WO-2020042995-A1 | HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | STING1 1/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | STING1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.